UNSPSC 51383901: Clonixeril

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H17CLN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XVF42I68OX, more generally known as clonixeril. European Medicines Agency schedules clonixeril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06733MIG. The term CLONIXERIL is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 24, no. 11 1970, list 10.

UNSPSC 51383901 Clonixeril, a Commodity code, does not align with the recent state and local procurement activity posted under it. The code nominally describes a specific pharmaceutical compound, yet the three most recent solicitations tagged to this code request naloxone and drug deactivation systems, therapeutic pharmacy initiative vendor capabilities, and generic multi-source pharmaceuticals and over-the-counter products—none of which are clonixeril. State and local procurement systems appear to have misclassified these opportunities, or the code has been applied broadly to pharmaceutical procurement categories rather than to the specific drug it nominates. The actual buying activity under this code tag spans health department naloxone supply, state pharmacy benefit management, and cooperative purchasing alliance pharmaceutical contracting, but none of the solicitations address clonixeril specifically.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026; and the Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs. The issuing bodies span county health departments, state cooperative purchasing vehicles, and state health agencies. Given the mismatch between the code's nominal scope and the actual opportunities posted under it, firms should verify code assignment with the issuing body before pursuing any opportunity tagged to 51383901.